Pneumonia prevention interventions such as proper oral care, head-of-bed elevation, and incentive spirometry, are not being provided to most patients outside the ICU, leading to greater than two-thirds of hospital-acquired pneumonia.
Investigators conducted a quasi-experimental, retrospective study of adult patients with COVID-19 pneumonia to evaluate antibiotic use for community-acquired bacterial pneumonia following the release of guidelines.
Researchers compared trends in antibiotic prescription rates during the period preceding the pneumococcal conjugate vaccine (PCV), as well as the early and late PCV periods, among Jewish vs Bedouin children.
Researchers report findings from SAATELLITE, a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that assessed the safety and efficacy of suvratoxumab for Staphylococcus aureus pneumonia.
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.